Shares of Epizyme Inc. (EPZM) have lost 50% of their value over the last 7 months compared to the 1.2 % gain of the iShares Nasdaq Biotechnology ETF (IBB) index during the same period.
Epizyme is a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer and other serious diseases. Epigenetic therapy is a novel therapeutic approach that focuses on changes in DNA expression without altering the makeup of the genes themselves.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com